1. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee
- Author
-
Pass, Hi, Giroux, D, Kennedy, C, Ruffini, Enrico, Cangir, Ak, Rice, D, Asamura, H, Waller, D, Edwards, J, Weder, W, Hoffmann, H, van Meerbeeck JP, Rusch, Vw, IASLC Staging Committee, Participating, Institutions, Scagliotti, Giorgio Vittorio, University of Zurich, and Pass, Harvey I
- Subjects
EXPRESSION ,Mesothelioma ,Pulmonary and Respiratory Medicine ,Registry ,Prognostic variable ,medicine.medical_specialty ,Staging ,10255 Clinic for Thoracic Surgery ,INTERNATIONAL-ASSOCIATION ,Population ,PHASE-II TRIALS ,610 Medicine & health ,VALIDATION ,LUNG-CANCER ,Medicine and Health Sciences ,medicine ,Adjuvant therapy ,Stage (cooking) ,Lung cancer ,education ,education.field_of_study ,business.industry ,Prognosis ,medicine.disease ,Surgery ,Log-rank test ,TO-LYMPHOCYTE RATIO ,Oncology ,2740 Pulmonary and Respiratory Medicine ,VOLUME ,SURVIVAL ,Malignant Pleural Mesothelioma ,2730 Oncology ,Radiology ,EXTRAPLEURAL PNEUMONECTOMY ,Lung cancer staging ,business ,MALIGNANT MESOTHELIOMA - Abstract
Introduction: The staging system for malignant pleural mesothelioma is controversial. To revise this system, the International Association for the Study of Lung Cancer Staging Committee developed an international database. This report analyzes prognostic variables in a surgical population, which are supplementary to previously published CORE variables (stage, histology, sex, age, and type of procedure). Methods: Supplementary prognostic variables were studied in three scenarios: (1) all data available, that is, patient pathologically staged and other CORE variables available (2) only clinical staging available along with CORE variables, and (3) only age, sex, histology, and laboratory parameters are known. Survival was analyzed by Kaplan-Meier, prognostic factors by log rank and stepwise Cox regression modeling after elimination of nonsignificant variables. p value less than 0.05 was significant. Results: A total of 2141 patients with best tumor, node, metastasis (TNM) stages (pathologic with/without clinical staging) had nonmissing age, sex, histology, and type of surgical procedure. Three prognostic models were defined. Scenario A (all parameters): best pathologic stage, histology, sex, age, type of surgery, adjuvant treatment, white blood cell count (WBC) (>= 15.5 or not), and platelets (>= 400 k or not) (n = 550). Scenario B (no surgical staging): clinical stage, histology, sex, age, type of surgery, adjuvant treatment, WBC, hemoglobin (
- Published
- 2014
- Full Text
- View/download PDF